Latest News on STOK

Financial News Based On Company


Advertisement
Advertisement

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - November 17, 2026

https://www.biospace.com/press-releases/stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-november-17-2026
Stoke Therapeutics announced the grant of stock options to eleven new employees, effective November 16, 2026, as an inducement for their employment. These grants cover 99,050 shares of common stock at an exercise price of $26.63 per share, vesting over a four-year period. The action is in accordance with Nasdaq Listing Rule 5635(c)(4).

Four Wellington entities report the same passive stake in Stoke Therapeutics (STOK).

https://www.stocktitan.net/sec-filings/STOK/schedule-13g-a-stoke-therapeutics-inc-amended-passive-investment-disc-e8d327b20e7c.html
Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP have jointly reported an amended passive investment disclosure in Stoke Therapeutics (STOK). Each entity beneficially owns 4,681,855 common shares, representing 7.26% of the class. The filing indicates shared voting and dispositive powers, with clients of Wellington investment advisers owning the securities of record.

Form SCHEDULE 13G/A Stoke Therapeutics, Inc. Filed by: RTW INVESTMENTS, LP

https://www.streetinsider.com/SEC+Filings/Form+SCHEDULE+13GA+Stoke+Therapeutics%2C+Inc.+Filed+by%3A+RTW+INVESTMENTS%2C+LP/27349367.html
RTW Investments, LP and Roderick Wong, M.D., have filed an Amendment No. 8 to Schedule 13G regarding their beneficial ownership in Stoke Therapeutics, Inc. As of September 30, 2026, they collectively own 6,537,475 shares, representing 9.9% of the class of Common Stock. This filing indicates their shared voting and dispositive power over these shares, acquired and held in the ordinary course of business without the purpose of changing or influencing control.

A 9.99% ownership cap limits warrant exercise for a Stoke Therapeutics (STOK) investor.

https://www.stocktitan.net/sec-filings/STOK/schedule-13g-a-stoke-therapeutics-inc-amended-passive-investment-disc-ff4b31c6dc3d.html
RTW Investments, LP and Roderick Wong have filed an amended beneficial-ownership report for Stoke Therapeutics (STOK), indicating a 9.99% stake with shared voting and dispositive power over 6,537,475 shares. This includes the assumption of exercising warrants for 913,950 shares, though a 9.99% ownership cap prevents the full exercise of these warrants if it would exceed that threshold. The reported percentage is based on 64,526,242 shares outstanding as of July 30, 2026.

RTW Investments and Roderick Wong Reveal 9.99% Stake in Stoke Therapeutics

https://kalkinemedia.com/us/news/announcements/rtw-investments-and-roderick-wong-reveal-999-stake-in-stoke-therapeutics
RTW Investments, LP and Roderick Wong have disclosed a 9.99% beneficial ownership stake in Stoke Therapeutics, Inc., as detailed in an Amendment No. 8 to Schedule 13G filed with the SEC on November 16, 2026. This stake, totaling 6,537,475 shares, includes warrants and is capped at 9.99% ownership according to warrant terms. The filing indicates shared voting and dispositive power over these shares, which were acquired in the ordinary course of business.
Advertisement

Technical Reactions to STOK Trends in Macro Strategies

https://news.stocktradersdaily.com/news_release/17/Technical_Reactions_to_STOK_Trends_in_Macro_Strategies_111526040402_1794733442.html
This report analyzes Stoke Therapeutics Inc. (NASDAQ: STOK) using AI models, identifying mixed sentiment and potential choppiness. It outlines three distinct trading strategies—Position Trading (long), Momentum Breakout (breakout), and Risk Hedging (short)—with specific entry, target, and stop levels. The analysis also highlights an exceptional risk-reward short setup targeting 13.4% downside.

Stoke Therapeutics (STOK) Heads To Guggenheim, Is The 42% Undervaluation Case Convincing?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/stoke-therapeutics-stok-heads-to-guggenheim-is-the-42-underv
Stoke Therapeutics (STOK) is set to present at the 3rd Annual Guggenheim Healthcare Innovation Conference, with Simply Wall St's analysis suggesting the stock is 41.9% undervalued against analyst consensus, anchoring fair value at $45.10. This bullish outlook hinges on successful Phase 3 Dravet data and favorable rare disease pricing, while acknowledging recent short-term share price cooling despite long-term gains. Investors are encouraged to review underlying numbers and key risks to form their own stance.

Stoke Therapeutics (NASDAQ:STOK) Shares Break Below 50-Day Moving Average - Should You Sell?

https://www.marketbeat.com/instant-alerts/price-stoke-therapeutics-nasdaq-stok-shares-break-below-50-day-moving-average-should-you-sell-2026-11-13/
Stoke Therapeutics (NASDAQ:STOK) shares have fallen below their 50-day moving average, trading at $26.20, below the $26.52 average. Despite missing Q3 EPS expectations, the company exceeded revenue forecasts, and analyst sentiment remains largely positive with a "Moderate Buy" consensus and an average price target of $44.17. However, recent insider transactions show General Counsel and a Director selling shares to cover tax obligations from equity awards.

Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock Has Consensus Target Price of $44.17 According to Brokerages

https://www.marketbeat.com/instant-alerts/consensus-stoke-therapeutics-inc-nasdaq-stok-stock-has-consensus-target-price-of-4417-according-to-brokerages-2026-11-12/
Stoke Therapeutics, Inc. (NASDAQ:STOK) has received a "Moderate Buy" consensus rating from eleven brokerages, with an average 1-year price target of $44.17. While the company's recent quarterly earnings reported a loss of $1.08 per share, missing estimates, its revenue of $11.26 million surpassed expectations. Insider transactions show recent sales by a director and an insider, but institutional investors have generally increased their holdings.

How Wider Losses At Stoke Therapeutics (STOK) Have Changed Its Investment Story

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/how-wider-losses-at-stoke-therapeutics-stok-have-changed-its
Stoke Therapeutics (STOK) reported wider losses in Q3 2026, with a net loss of US$73.64 million for the quarter and US$185.27 million for the first nine months, despite a slight increase in quarterly sales. This significant swing from prior year profit to a substantial loss highlights the company's reliance on future pipeline progress and collaboration revenue. The investment narrative remains heavily dependent on late-stage data and regulatory decisions for zorevunersen, with extended timelines now carrying higher stakes due to increased funding needs.
Advertisement

One Stoke Therapeutics (STOK) holder reports 4.82 million shares but zero voting power.

https://www.stocktitan.net/sec-filings/STOK/schedule-13g-a-stoke-therapeutics-inc-amended-passive-investment-disc-8a195ff38b86.html
FMR LLC has reported a 7.5% beneficial ownership stake in Stoke Therapeutics (STOK), holding 4,820,462 shares, with sole voting power over 4,819,851 shares. Separately, Abigail P. Johnson is listed with the same beneficial ownership and sole dispositive power, but explicitly states zero sole or shared voting power over the shares. This disclosure details the ownership structure and voting rights for a significant portion of the company's common stock.

Price-Driven Insight from (STOK) for Rule-Based Strategy

https://news.stocktradersdaily.com/news_release/78/Price-Driven_Insight_from_STOK_for_Rule-Based_Strategy_110526043001_1793871001.html
This article provides a price-driven insight into Stoke Therapeutics Inc. (NASDAQ: STOK) for rule-based trading strategies. It outlines three distinct AI-generated strategies—Position Trading (LONG), Momentum Breakout (BREAKOUT), and Risk Hedging (SHORT)—with specific entry, target, and stop-loss levels. The analysis highlights a strong near- and mid-term sentiment but a weak long-term outlook for STOK, along with an exceptional risk-reward short setup.

HC Wainwright Has Negative Estimate for STOK FY2026 Earnings

https://www.marketbeat.com/instant-alerts/estimates-hc-wainwright-has-negative-estimate-for-stok-fy2026-earnings-2026-11-04/
HC Wainwright has lowered its FY2026 earnings per share estimate for Stoke Therapeutics (NASDAQ:STOK) to a loss of $3.93, a reduction from its previous forecast of a $3.35 loss. This negative adjustment comes despite the company reporting revenue that topped expectations in its latest quarterly earnings, though it missed EPS estimates. The overall analyst sentiment for STOK remains "Moderate Buy" with an average price target of $44.17.

Stoke Therapeutics 3Q 2026: Revenue $11.3M, Net loss $73.6M, EPS $(1.08) — 10-Q Summary

https://www.tradingview.com/news/tradingview:2f2cc52288bc8:0-stoke-therapeutics-3q-2026-revenue-11-3m-net-loss-73-6m-eps-1-08-10-q-summary/
Stoke Therapeutics reported third-quarter 2026 revenue of $11.3 million, a 5.9% increase year-over-year, but its net loss widened significantly to $73.6 million, resulting in a diluted loss per share of $(1.08). The company also provided updates on its clinical trials, including the closed enrollment for the EMPEROR Phase 3 study of zorevunersen and the advancement of the OSPREY Phase 1 study for STK-002, with plans for a potential U.S. launch of zorevunersen in early 2028.

Stoke Therapeutics to Present at Upcoming Investor Conferences in November 2026

https://www.biospace.com/press-releases/stoke-therapeutics-to-present-at-upcoming-investor-conferences-in-november-2026
Stoke Therapeutics, Inc. announced that its CEO and Chief Patient Officer will present at two upcoming investor conferences in November 2026: the Guggenheim 3rd Annual Healthcare Innovation Conference and the Jefferies London Global Healthcare Conference. The biotechnology company is focused on restoring protein expression with RNA medicine, with its lead investigational medicine, zorevunersen, in development for Dravet syndrome. Live webcasts and archived replays will be available on the company's investor relations website.
Advertisement

Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates

https://www.biospace.com/press-releases/stoke-therapeutics-announces-third-quarter-2026-financial-results-and-provides-business-updates
Stoke Therapeutics announced its third-quarter 2026 financial results, highlighting significant progress in its Phase 3 EMPEROR study for zorevunersen, an investigational medicine for Dravet syndrome, with a data readout anticipated in Q3 2027. The company also provided updates on its STK-002 program for Autosomal Dominant Optic Atrophy (ADOA), with initial safety and efficacy data expected in H1 2027. Stoke reported $358.8 million in cash, cash equivalents, and marketable securities, projected to fund operations into early 2028.

Stoke Therapeutics Expects Q3 2027 EMPEROR Readout and NDA Filing

https://www.tokenpost.com/news/business/44340
Stoke Therapeutics anticipates reporting results from its EMPEROR study in Q3 2027 and submitting a New Drug Application (NDA) in the second half of the year, aiming for potential U.S. approval in early 2028. The company has aligned with the FDA on NDA plans, with 110 of 162 enrolled patients completing a week 28 visit. Stoke ended Q3 2026 with $358.8 million in cash, expected to fund operations into early 2028.

Stoke Therapeutics, Inc. (STOK) Misses Q3 EPS by 15c

https://www.streetinsider.com/Earnings/Stoke+Therapeutics%2C+Inc.+%28STOK%29+Misses+Q3+EPS+by+15c/27258305.html
Stoke Therapeutics, Inc. (STOK) reported its Q3 earnings, missing analyst EPS estimates by $0.15 with a reported EPS of ($1.08) against an estimate of ($0.93). Despite the EPS miss, the company's revenue for the quarter came in at $11.25 million, exceeding the consensus estimate of $8.21 million.

Stoke Therapeutics Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/10/62724574/stoke-therapeutics-q3-2026-earnings-call-transcript
Stoke Therapeutics reported a net loss of $73.6 million for Q3 2026, ending the quarter with $358.8 million in cash, expected to fund operations into early 2028. The EMPRA Phase 3 study for zarepinersen in Dravet syndrome is progressing, with 110 of 162 patients completing the primary endpoint and no discontinuations. The company also discussed plans for a rolling NDA submission for zarepinersen in 2027 and provided an update on STK-002 for autosomal dominant optic atrophy, with initial data anticipated in the first half of 2027.

Stoke Therapeutics earnings missed by $0.15, revenue topped estimates

https://www.investing.com/news/earnings/stoke-therapeutics-earnings-missed-by-015-revenue-topped-estimates-4985074
Stoke Therapeutics (NASDAQ: STOK) reported a third-quarter EPS of $-1.08, missing analyst estimates by $0.15, while revenue came in at $11.25M, surpassing the consensus estimate of $8.21M. The company's stock price closed at $26.35, experiencing declines of -8.70% over the last three months and -16.88% over the last twelve months. InvestingPro rates Stoke Therapeutics' financial health as "fair performance."
Advertisement

Stoke Therapeutics Posts Q3 2026 Results, Advances Dravet Trial

https://www.tradingview.com/news/tradingview:558a406e5bacf:0-stoke-therapeutics-posts-q3-2026-results-advances-dravet-trial/
Stoke Therapeutics reported Q3 2026 revenue of $11.3 million and a net loss of $73.6 million, or $1.08 per share. The company's cash reserves of $358.8 million are expected to fund operations into early 2028. Additionally, the Phase 3 EMPEROR study for zorevunersen in Dravet syndrome has completed primary analysis population enrollment, with results anticipated in Q3 2027.

Stoke Therapeutics (STOK) Projected to Announce Earnings on Thursday

https://www.marketbeat.com/instant-alerts/upcoming-stoke-therapeutics-stok-projected-to-announce-earnings-on-thursday-2026-10-24/
Stoke Therapeutics (NASDAQ:STOK) is anticipated to release its Q3 2026 earnings on Thursday, October 29th, with analysts projecting a loss of $0.9291 per share on $8.21 million in revenue. The company previously missed EPS estimates but exceeded revenue expectations in its last quarterly report. Shares are currently trading at $25.04, with a "Moderate Buy" consensus rating and a $44.25 price target from analysts, despite recent insider stock sales.

Stoke Therapeutics, Inc. Estimates – NASDAQ:STOK

https://www.tradingview.com/symbols/NASDAQ-STOK/financials-estimates/
This page provides financial estimates for Stoke Therapeutics, Inc. (NASDAQ: STOK), allowing users to explore reported financial data and analyst estimates across various financial statements and valuation metrics. It enables comparison of actual results with average, high, and low estimates, and visualization of trends over time for the income statement, balance sheet, and cash flow.

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates

https://www.biospace.com/press-releases/stoke-therapeutics-to-host-webcast-and-conference-call-to-discuss-third-quarter-2026-business-and-financial-updates
Stoke Therapeutics, a biotechnology company, announced it will host a webcast and conference call on Thursday, October 29, 2026, at 4:30 p.m. ET, to discuss its third quarter 2026 business and financial updates. The company is developing zorevunersen, an investigational medicine for Dravet syndrome, currently in a Phase 3 study. Interested analysts and investors can register or access a listen-only webcast on Stoke’s investor relations website.

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates

https://finance.yahoo.com/healthcare/articles/stoke-therapeutics-host-webcast-conference-120000989.html
Stoke Therapeutics, Inc. (Nasdaq: STOK) announced it will host a webcast and conference call on Thursday, October 29, 2026, at 4:30 p.m. ET, to provide business and financial updates for the third quarter of 2026. The company, which is developing RNA medicine zorevunersen for Dravet syndrome, will make the webcast available on its investor relations website. Analysts are invited to register for the Q&A session, while other participants can access a listen-only webcast.
Advertisement

Form 144 STOKE THERAPEUTICS For: 21 October By Investing.com

https://za.investing.com/news/stock-market-news/form-144-stoke-therapeutics-for-21-october-93CH-4518108
Investing.com published a notice regarding Form 144 for STOKE THERAPEUTICS, specifically for the activity on October 21. The article itself is very brief and primarily serves as an announcement for this regulatory filing. It includes a link to view comments and notes the stock symbol STOK, which saw a -2.57% change.

Form 144 STOKE THERAPEUTICS For: 21 October By Investing.com

https://au.investing.com/news/stock-market-news/form-144-stoke-therapeutics-for-21-october-93CH-4706299
This article from Investing.com announces the filing of Form 144 for STOKE THERAPEUTICS, specifically for activity on October 21. Form 144 is a notice of the intent to sell restricted securities, indicating potential insider transactions. The article provides the basic announcement without further details or analysis.

Form 144 Stoke Therapeutics, Inc. Filed by: Kaye Edward M. MD

https://www.streetinsider.com/SEC+Filings/Form+144+Stoke+Therapeutics%2C+Inc.+Filed+by%3A+Kaye+Edward+M.+MD/27217039.html
Edward M. Kaye, MD, a former affiliate of Stoke Therapeutics, Inc., has filed a Form 144 for the proposed sale of 1,496,042 shares of common stock with an aggregate market value of $38,418,358.56. These securities were acquired through the exercise of options under a registered plan on October 21, 2026, with the sale commencing on the same date. The filing also notes previous sales by Edward Kaye totaling 12,567 common shares on August 14, 2026, for gross proceeds of $402,521.01.

A former affiliate plans to exercise options without cash and sell Stoke Therapeutics (STOK) shares.

https://www.stocktitan.net/sec-filings/STOK/144-stoke-therapeutics-inc-sec-filing-58cc71a5db1d.html
Edward Kaye, a former affiliate of Stoke Therapeutics (STOK), has filed a Rule 144 notice indicating a planned sale of 1,496,042 common shares, valued at approximately $38.4 million. These sales are set to commence on October 21, 2026, following a cashless exercise of options under a registered plan. Kaye previously sold 12,567 common shares on August 14, 2026, for over $402,000.

Stoke Therapeutics eyes 2027 readout for potential first disease-modifying Dravet syndrome therapy.

https://pluang.com/en/news-feed/stoke-therapeutics-pasar-salah-baca-kemenangan-fda-kunci
Stoke Therapeutics is preparing for a significant 2027 data readout for zorevunersen, a potential first disease-modifying treatment for Dravet syndrome. The company is well-funded with $420 million in cash and a recent $65.7 million share sale, securing operations into early 2028. The FDA's acceptance of a cognition/behavior endpoint for the EMPEROR trial significantly de-risks the regulatory pathway, differentiating zorevunersen from current symptomatic treatments.
Advertisement

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - October 16, 2026

https://www.biospace.com/press-releases/stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-october-16-2026
Stoke Therapeutics (Nasdaq: STOK) announced inducement grants of stock options to new employees, including newly-appointed Senior Vice President, Chief Information Officer, Stephen Aschettino, and seventeen other new employees. These grants were made effective October 15, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4). The options for Mr. Aschettino cover 70,000 shares, and for the other seventeen employees, an aggregate of 175,920 shares, all with an exercise price of $24.61 per share and vesting over a four-year period.

Stoke Therapeutics grants 245,920 options on Stoke Therapeutics stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/stoke-therapeutics-grants-245-920-options-on-stoke-therapeutics-stock/70353064
Stoke Therapeutics granted 245,920 stock options to 18 new employees on October 16, 2026, including 70,000 for its new Chief Information Officer. This event follows recent clinical updates, such as the completion of the first two OSPREY dose cohorts for STK-002. The company is set to report its third-quarter results on November 3, 2026, with its second-quarter revenue exceeding expectations.

Assenagon Asset Management S.A. Acquires 52,394 Shares of Stoke Therapeutics, Inc. $STOK

https://www.marketbeat.com/instant-alerts/filing-assenagon-asset-management-sa-acquires-52394-shares-of-stoke-therapeutics-inc-stok-2026-10-18/
Assenagon Asset Management S.A. increased its stake in Stoke Therapeutics (NASDAQ:STOK) by 4.6% in the third quarter, acquiring an additional 52,394 shares to bring its total holdings to 1.18 million shares valued at $30.7 million. Despite the company reporting a quarterly loss of $0.93 per share, missing estimates, its revenue of $9.32 million surpassed forecasts. Analysts largely maintain a "Moderate Buy" rating for STOK, with an average price target of $44.25.

Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock Has Average Target Price of $44.25

https://www.marketbeat.com/instant-alerts/consensus-stoke-therapeutics-inc-nasdaq-stok-stock-has-average-target-price-of-4425-2026-10-18/
Stoke Therapeutics, Inc. (NASDAQ:STOK) has a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $44.25, significantly above its current trading price of $24.17. The company recently missed earnings expectations but exceeded revenue forecasts, and institutional ownership has increased while insiders have sold shares primarily for tax obligations.

What Stoke Therapeutics (STOK)'s ADOA Trial Update Means For Shareholders

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/what-stoke-therapeutics-stoks-adoa-trial-update-means-for-sh/amp
Stoke Therapeutics recently presented new preclinical and early clinical data for its antisense drug STK-002 in Autosomal Dominant Optic Atrophy (ADOA) and provided an update on the Phase 1 OSPREY trial. While STK-002 expands the company's pipeline, the main value driver remains zorevunersen in Dravet syndrome, with its Phase 3 EMPEROR readout and upcoming NDA filing. The company faces the challenge of managing both an expensive late-stage epilepsy program and an early-stage ophthalmology effort simultaneously, alongside inherent clinical, payer, and partner risks.
Advertisement

Liquidity Mapping Around (STOK) Price Events

https://news.stocktradersdaily.com/news_release/24/Liquidity_Mapping_Around_STOK_Price_Events_101526074602_1792107962.html
This article provides a liquidity mapping analysis for Stoke Therapeutics Inc. (NASDAQ: STOK), highlighting weak near and mid-term sentiment and a neutral long-term outlook. It presents AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis to guide investors. The analysis indicates elevated downside risk due to the absence of additional long-term support signals.

Stoke presents STK-002 data. Stoke Therapeutics stock is valued at USD 1.5 billion

https://www.ad-hoc-news.de/boerse/news/nebenwerte/stoke-presents-stk-002-data-stoke-therapeutics-stock-is-valued-at-usd-1-5-billion/70329546
Stoke Therapeutics presented new data for its STK-002 drug candidate at the American Academy of Ophthalmology meeting. The company's stock was trading at EUR 20.83 on October 15, 2026, with a market capitalization of USD 1.5 billion. Key upcoming events include the completion of the STK-002 Phase 1 study by year-end 2026, initial safety and efficacy results in H1 2027, and Q3 2026 earnings reporting on November 3, 2026.

Stoke therapeutics CMO Barry Ticho sells $27,493 in stock

https://www.investing.com/news/insider-trading-news/stoke-therapeutics-cmo-barry-ticho-sells-27493-in-stock-93CH-4945416
Barry Ticho, Chief Medical Officer at Stoke Therapeutics, Inc. (NASDAQ:STOK), recently sold 1,051 shares of company stock for a total of $27,493. This transaction was conducted under a Rule 10b5-1 trading plan adopted in November 2025. Despite the sale, the company is advancing its lead Dravet syndrome program, zorevunersen, towards a potential U.S. launch in early 2028, with analyst ratings from Goldman Sachs and Canaccord reiterating "Buy" ratings.

Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK) and AbbVie (ABBV)

https://www.theglobeandmail.com/investing/markets/stocks/ABBV/pressreleases/6781194/analysts-offer-insights-on-healthcare-companies-stoke-therapeutics-stok-and-abbvie-abbv/
Two analysts have issued bullish sentiments on healthcare companies Stoke Therapeutics (STOK) and AbbVie (ABBV). BTIG analyst Thomas Shrader maintained a Buy rating on Stoke Therapeutics with a $39.00 price target, while BMO Capital analyst Evan Seigerman maintained a Buy rating on AbbVie with a $300.00 price target. Both companies received a Strong Buy analyst consensus rating.

Stoke Therapeutics (STOK) Puts STK 002 Data In Focus Following An Undervalued Narrative

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/stoke-therapeutics-stok-puts-stk-002-data-in-focus-following
Stoke Therapeutics (STOK) recently presented new clinical data for its RNA-based therapy STK-002 for Autosomal Dominant Optic Atrophy at the AAO 2026 meeting. Despite a recent share price decline, the stock is considered 50.1% undervalued by many, with a fair value estimate of $45.10 against a current price of $22.50. Investors are weighing the potential of its rare disease pipeline against trial risks and ongoing losses.
Advertisement

Stoke Therapeutics (NASDAQ:STOK) Shares Down 7.1% - Time to Sell?

https://www.marketbeat.com/instant-alerts/price-stoke-therapeutics-nasdaq-stok-shares-down-71-time-to-sell-2026-10-13/
Stoke Therapeutics (NASDAQ:STOK) saw its shares decline by 7.1% in mid-day trading. Despite this drop and missing EPS expectations, the stock holds a "Moderate Buy" consensus rating from analysts with an average price target of $44.25. The company remains unprofitable, and recent insider transactions show sales of shares by executives.

Form 4 Stoke Therapeutics Inc: Barry Ticho (CHIEF MEDICAL OFFICER) For: 1 October

https://ng.investing.com/news/stock-market-news/form-4-stoke-therapeutics-inc-barry-ticho-chief-medical-officer-for-1-october-93CH-2732721
This article reports on a Form 4 filing for Stoke Therapeutics Inc., detailing a transaction involving Chief Medical Officer Barry Ticho on October 1st. Form 4 filings are regulatory documents that disclose changes in ownership of company stock by insiders. The article indicates that additional details of the transaction would be available within the filing itself.

Form 4 Stoke Therapeutics Inc: Jonathan Allan (GENERAL COUNSEL & CORP SEC) For: 2 October

https://in.investing.com/news/stock-market-news/form-4-stoke-therapeutics-inc-jonathan-allan-general-counsel--corp-sec-for-2-october-93CH-5629551
This article reports that Jonathan Allan, General Counsel & Corporate Secretary for Stoke Therapeutics Inc., filed a Form 4 for the 2nd of October. A Form 4 is a document filed with the SEC by company insiders to report changes in their ownership of company stock. The article is a brief announcement without further details on the nature of the transaction.

Stoke Therapeutics shares STK-002 data for eye disorder at AAO

https://www.streetinsider.com/Corporate+News/Stoke+Therapeutics+shares+STK-002+data+for+eye+disorder+at+AAO/27174074.html
Stoke Therapeutics presented preclinical and early clinical data for STK-002, an experimental treatment for autosomal dominant optic atrophy (ADOA), at the American Academy of Ophthalmology 2026 Annual Meeting. ADOA is a rare inherited optic nerve disorder with no approved treatments, caused by OPA1 gene variants. The data included findings from the FALCON natural history study, showing increased mitochondrial oxidative stress in ADOA patients, and preclinical data demonstrating improved mitochondrial function and OPA1 protein expression with STK-002. The company also provided an update on the Phase 1 OSPREY study, with initial safety and efficacy data expected in the first half of 2027.

Stoke Therapeutics presents data on ADOA treatment STK-002 By Investing.com

https://ca.investing.com/news/stock-market-news/stoke-therapeutics-presents-data-on-adoa-treatment-stk002-93CH-4876061
Stoke Therapeutics (NASDAQ:STOK) presented data on its experimental treatment STK-002 for Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology 2026 Annual Meeting. Dosing is complete for the first two cohorts of its Phase 1 OSPREY study, with the third cohort expected to finish by year-end 2026, and initial safety and efficacy data from cohorts three and four anticipated in the first half of 2027. STK-002 is an antisense oligonucleotide designed to increase OPA1 protein levels, addressing the primary cause of ADOA, an inherited optic nerve disorder affecting vision for which there are currently no approved treatments.
Advertisement

Stoke Therapeutics (STOK) Short Interest & Short Float | Updated Oct 2026

https://www.marketbeat.com/stocks/NASDAQ/STOK/short-interest/
As of September 30, 2026, Stoke Therapeutics (STOK) reported a short interest of 11.51 million shares, representing 19.72% of its public float, marking a 3.19% increase from the previous report. The short interest ratio stands at 10.2 days to cover, indicating a significant level of pessimism among investors. This data is critical for traders to assess market sentiment and potential volatility for STOK.

Stoke Therapeutics Q3 2026 Earnings Date and Estimates

https://www.marketbeat.com/earnings/reports/2026-11-3-stoke-therapeutics-inc-stock/
Stoke Therapeutics (STOK) is scheduled to report its Q3 2026 earnings on Tuesday, November 3, 2026, before the market opens. Analysts anticipate the company will post earnings of -$0.88 per share on revenues of $8.21 million. This compares to -$0.65 per share on revenues of $10.63 million in the same quarter last year.

Stoke Therapeutics (STOK) Could Be 46% Below Fair Value As Clinical Catalysts Build

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/stoke-therapeutics-stok-could-be-46-below-fair-value-as-clin/amp
Stoke Therapeutics (STOK) is attracting attention due to new clinical data for its eye drug candidate STK-002, despite recent stock price declines. The company is considered 46% undervalued with a fair value of $45.10 against its current price of $24.37, based on an aggressive revenue and margin path, though potential risks like trial delays or underwhelming data could challenge this bullish outlook. Investors are advised to consider both the rewards and warning signs before making investment decisions.

STOK: Stoke Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas

https://stocktwits.com/symbol/STOK
This article provides the latest stock price, analysis, news, and trading ideas for Stoke Therapeutics Inc (STOK). It highlights the company's financial data, recent FDA meeting success for its investigational drug Zorevunersen for Dravet Syndrome, and analyst sentiment. The article also mentions upcoming presentations for STK-002 and a new board appointment.

Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

https://www.biospace.com/press-releases/stoke-therapeutics-announces-completion-of-successful-meeting-with-the-fda-to-align-on-planned-u-s-nda-for-zorevunersen-an-investigational-medicine-for-the-treatment-of-dravet-syndrome
Stoke Therapeutics has completed a successful meeting with the FDA to align on the planned U.S. New Drug Application (NDA) for zorevunersen, an investigational medicine for Dravet syndrome. The company plans to use a multicomponent assessment of four Vineland-3 subdomains to evaluate changes in cognition and behavior in the Phase 3 EMPEROR study. A Phase 3 readout is anticipated in Q3 2027, with the NDA submission planned for H2 2027, potentially leading to U.S. approval and launch in early 2028.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement